Login / Signup

Improving olaparib exposure to optimize adverse effects management.

Marylise SterléAlicja PuszkielChloé BurlotEva PereiraAudrey BellesoeurSixtine De PercinGuillaume BeinseJean-David FumetLaure FavierJulie NiogretBenoit BlanchetBernard RoyerLeïla Bengrine-LefevreAntonin Schmitt
Published in: Therapeutic advances in medical oncology (2024)
Based on real-world data, we were able to properly describe the time course of haemoglobinaemia and plasma creatininaemia during olaparib treatment.
Keyphrases
  • combination therapy
  • replacement therapy
  • smoking cessation